NEW YORK (GenomeWeb) – Molecular diagnostics firm Rosetta Genomics has been notified that it has failed to meet the Nasdaq's minimum bid price requirement for continued listing on the exchange, the company disclosed yesterday in a filing with the US Securities and Exchange Commission.
According to Rosetta, its stock's closing bid price per share has been below the required $1 minimum for the past 30 consecutive days in violation of Nasdaq rules. The firm said it has been give 180 calendar days to regain compliance, which would require its shares meet or exceed $1 per share for at least 10 consecutive days. If it fails to do so, it may request an additional 180-day grace period or face delisting.
During early morning trading on Friday, shares of Rosetta were unchanged from its Thursday close at $.75.